Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
(2006) In Leukemia 20(1). p.42-47- Abstract
- Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking. The remission intention ( RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown. The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries. Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region ( range... (More)
- Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking. The remission intention ( RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown. The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries. Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region ( range 36-76%) and the two-year overall survival, with no censored observations (6-21%) ( v 2 for trend = 11.3, P < 0.001; r(2) = 0.86, P < 0.02, nonparametric). A 1-month landmark analysis showed significantly better survival in regions with higher RI rates ( P = 0.003). Differences could not be explained by demographics, and was found in both de novo and secondary leukemias. The 5-year survival of the overall population aged 70-79 years was similar between the regions. Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/148919
- author
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- acute myeloid leukemia, elderly, remission induction, population based, palliation
- in
- Leukemia
- volume
- 20
- issue
- 1
- pages
- 42 - 47
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000233956600006
- pmid:16327841
- scopus:33644985390
- ISSN
- 1476-5551
- DOI
- 10.1038/sj.leu.2404004
- language
- English
- LU publication?
- yes
- id
- f1b7fb25-17c2-48cb-8d85-0ed814ff36b3 (old id 148919)
- date added to LUP
- 2016-04-01 15:22:37
- date last changed
- 2022-03-30 00:53:36
@article{f1b7fb25-17c2-48cb-8d85-0ed814ff36b3, abstract = {{Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking. The remission intention ( RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown. The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries. Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region ( range 36-76%) and the two-year overall survival, with no censored observations (6-21%) ( v 2 for trend = 11.3, P < 0.001; r(2) = 0.86, P < 0.02, nonparametric). A 1-month landmark analysis showed significantly better survival in regions with higher RI rates ( P = 0.003). Differences could not be explained by demographics, and was found in both de novo and secondary leukemias. The 5-year survival of the overall population aged 70-79 years was similar between the regions. Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction.}}, author = {{Juliusson, Gunnar and Billstrom, R and Gruber, A and Hellstrom-Lindberg, E and Hoglund, M and Karlsson, K and Stockelberg, D and Wahlin, A and Astrom, M and Arnesson, C and Brunell-Abrahamsson, U and Carstensen, J and Fredriksson, E and Holmberg, E and Nordenskjold, K and Wiklund, F}}, issn = {{1476-5551}}, keywords = {{acute myeloid leukemia; elderly; remission induction; population based; palliation}}, language = {{eng}}, number = {{1}}, pages = {{42--47}}, publisher = {{Nature Publishing Group}}, series = {{Leukemia}}, title = {{Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.}}, url = {{http://dx.doi.org/10.1038/sj.leu.2404004}}, doi = {{10.1038/sj.leu.2404004}}, volume = {{20}}, year = {{2006}}, }